The U.S. FDA approved Sildenafil , a selective inhibitor of cGMP specific phosphodiesterase type 5 ( PDE5 ) , for the treatment of PAH in 2005 .
Sildenafil , a selective inhibitor of cGMP specific phosphodiesterase type 5 ( PDE5 ) , was approved for the treatment of PAH in 2005 .